Texas

According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!

An experimental vaccine for respiratory syncytial virus (RSV) showed positive results in a Phase I clinical trial. Researchers from The University of Texas at Austin and others reported that a single dose of the vaccine produced significant evidence of RSV-neutralizing antibodies that were sustained for several months.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Researchers from UT Southwestern discovered that PARP inhibitors can also impact the cellular production of ribosomes, a protein cancer cells depend upon.

There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?

In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.

Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regions. Take a look.

For quite some time, the focus of the cause of Alzheimer’s disease was on beta-amyloid, a protein that accumulates in the brains of individuals with the disease and which appears to cause at least some of the damage that results in memory and cognition issues. There are other candidates, and research appears to be heating up on the role of inflammation.

As the 2020 election heats up, candidates for president are unveiling their plans to lower prescription drug prices.

Although the American public, Congress and the Trump administration have pressed for meaningful legislation over drug pricing, time is running out this year.